BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. AMD
5. USO
6. META
7. AMC
8. MSFT
9. ACN
10. AMZN

Go back to BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) Delayed: 64.03 +0.09 (0.14%)
Previous Close $63.94    52 Week High $108.96 
Open $64.35    52 Week Low $62.12 
Day High $64.96    P/E N/A 
Day Low $63.58    EPS $-1.27 
Volume 388,579